Development and Validation of Eltrombopag Determination in Human Plasma Blood by HPLC-MS Method
Разработка и регистрация лекарственных средств, 2022 Introduction. "Eltrombopag" is a thrombopoietin receptor agonist (TPO-RA) that is approved for the treatment of immune thrombocytopenic purpura (ITP).
А. М. AL-Dhuraibi +2 more
doaj +2 more sources
Biosensors, 2023 Eltrombopag is a powerful adjuvant anticancer drug used in treating MS (myelodysplastic syndrome) and AML (acute myeloid leukemia) diseases. In this study, the interaction mechanism between eltrombopag and DNA was studied by voltammetry, spectroscopic ...
Somaye Cheraghi +8 more
doaj +2 more sources
Turkish Journal of Hematology, 2022 Objective: Eltrombopag remains a prominent option in the treatment of steroid-dependent or steroid-refractory immune thrombocytopenia (ITP) patients. Unfortunately, not all patients respond to eltrombopag.
Mehmet Baysal +4 more
doaj +2 more sources
Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors [PDF]
Farmacia Hospitalaria, 2015 Purpose: To describe the results of the off-label use of eltrombopag in patients with solid tumors and thrombocytopenia that limits chemotherapy. Methods: Retrospective observational study including all patients with solid tumors who were treated with
María Henar García Lagunar +5 more
doaj +2 more sources
Efficacy of eltrombopag in combination with recombinant human thrombopoietin (rhTPO) for lymphoma patients with chemotherapy-induced thrombocytopenia [PDF]
Frontiers in PharmacologyPurposeTo observe the efficacy and adverse reactions of eltrombopag combined with rhTPO in the treatment of lymphoma patients with chemotherapy - induced thrombocytopenia (CIT).MethodsA retrospective study was performed on the clinical data of 61 ...
Qiuhua Zhu +10 more
doaj +2 more sources
Sustained Erythroid Response to Eltrombopag in Low-Risk Myelodysplastic Neoplasms With Severe Anemia and Thrombocytopenia: A Case Report [PDF]
Case Reports in HematologyEltrombopag has been already employed for thrombocytopenia in myelodysplastic neoplasms (MDS), but its role and efficacy in improving other cytopenias are still unknown.
Ambra Di Veroli +7 more
doaj +2 more sources
Frontiers in Medicine, 2020 Background: The thrombopoietin receptor agonist eltrombopag has been shown to be safe and effective for children with chronic immune thrombocytopenia (ITP).
Lucia Dora Notarangelo +2 more
exaly +3 more sources
Efficacy and safety comparison of hetrombopag and eltrombopag in children with cancer therapy-induced thrombocytopenia: a single-center retrospective study [PDF]
Frontiers in MedicineObjectiveTo compare the efficacy and safety of hetrombopag and eltrombopag in children with cancer therapy-induced thrombocytopenia (CTIT), and to explore the clinical value of eltrombopag for this specific pediatric population given the current lack of ...
Li-Ting Yu +8 more
doaj +2 more sources
Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain [PDF]
Farmacia Hospitalaria, 2020 Objective: Splenectomy, thrombopoietin receptor agonists and rituximab are the second-line treatments for steroid-resistant adult primary immune thrombocytopenia.
Eduardo Anguita +2 more
doaj +1 more source
Intelligent Pharmacy, 2023 Background: Eltrombopag, the first TPO-RA approved for the treatment of ITP, resulted in rapid and sustained increases in platelet counts, significant reductions in bleeding events and concomitant medications, and an acceptable tolerability profile. This
Lizong Li +8 more
doaj +1 more source